Please login to the form below

Not currently logged in
Email:
Password:

AZ agrees generics deal with Torrent

AstraZeneca is to enter into an agreement with Torrent Pharmaceuticals to purchase the licenses to a portfolio of generic medicines

AstraZeneca (AZ) has announced it is to enter into an agreement with Indian based drug makers Torrent Pharmaceuticals to purchase the licenses to a portfolio of generic medicines.

The deal will see the anglo-Swedish pharmaceutical giants obtain from Torrent the licenses and market authorisations for 18 products in nine countries, with AZ looking to 'capitalise' on the increasing prospects for pharmaceutical companies in emerging markets, including India.

In a statement, AZ claimed that emerging markets are "forecast to contribute around 70 per cent of pharmaceutical industry growth in the next five years, and branded generics represent approximately 50 per cent by value in these emerging markets."

As part of the deal, for which no financial details were disclosed, AZ will also gain the flexibility to add further products and new countries for which the company sees expansion opportunities.

Torrent, who currently produce and supply its products into more than 50 countries, will continue to manufacture the medicines.

Tony Zook, head of AstraZeneca's global commercial organisation, said: "In markets where consumers and physicians have a strong preference for trusted brands, we believe AstraZeneca's long-standing reputation for quality is a sustainable competitive advantage. Working in partnership with Torrent will extend the range of branded medicines we can offer to patients in emerging markets, where we see continuing opportunities for our business to grow."

11th March 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Evoke Kyne

Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...